Danone's Q1 Stability Masks Critical Strength in China

Core Conclusions

Danone’s first-quarter results met consensus expectations but revealed critical internal divergence. The standout performance in China (CNAO), the company's largest infant milk formula market, significantly exceeded expectations and provides a material offset to headwinds in Europe and the Middle East. Management's reiteration of full-year guidance signals confidence in this resilient growth pillar. The current valuation does not fully price in this structural strength, supporting an Overweight stance.

What the Market May Be Mispricing

The market is likely overestimating the impact of the European infant milk recall and Middle East conflict on Danone's aggregate growth, while underestimating the structural resilience and growth potential of its China Specialized Nutrition business. A forward P/E of 17.5x represents a limited 6.7% premium to the Staples sector average, inadequately reflecting the certainty and quality of earnings derived from this key market.

Evidence Chain

China's Infant Nutrition Business Demonstrated Exceptional Resilience. The core pillar of growth remained robust, with CNAO posting +10.3% LFL growth, surpassing the Visible Alpha consensus of +8.2%. This was primarily volume-driven (+10.5%), indicating strong market demand and execution despite sector-wide challenges. The investment implication is clear: China remains a dependable, high-single-digit growth engine that can buffer regional volatility, directly mitigating concerns over the European recall's global spillover.

Severe Regional Divergence Underpins the Global Story. Growth drivers were geographically split. The Americas delivered +3.4% LFL, beating consensus (+2.5%) on robust volume growth (+2.5%). Conversely, EMEA growth slowed sharply to +0.6%, with volume/mix down -1.4%, directly impacted by the European IMF recall and Middle East conflict. This divergence confirms that while Europe presents a near-term headwind, the Americas and Asia-Pacific franchises continue to perform, offering a balanced portfolio effect.

Reiterated Guidance Signals Underlying Confidence. Management reaffirmed its FY26 targets of +3-5% LFL sales growth and recurring operating income growing faster than sales. This guidance was maintained despite the EMEA headwinds, implying an expectation for recovery or, more likely, confidence that strength in other regions—particularly China and the Americas—will be sufficient to achieve the targets. This forward commitment reduces earnings uncertainty.

Key Disagreements & Risks

The primary risk remains the duration and potential indirect reputational impact of the European infant milk recall. A slowdown in the premiumization trend within China's IMF market could pressure growth and margins. Persistent soft pricing in North America (Q1 price -0.3%) poses a margin risk if volumes weaken. Finally, volatility in commodity costs and intensifying competition, including from private label, are ongoing sector-wide pressures.

Valuation & Trade Implications

At 17.5x CY26e P/E, the stock's premium to staples is modest and does not reflect the enhanced earnings certainty provided by China's outperformance. We maintain our Overweight rating and €78 price target. The resilience shown in Q1 supports the view that Danone can navigate regional challenges to meet its annual guidance, making the current risk/reward profile attractive.

Appendix: Key Data Summary